We’re creating unmatched value through enhanced treatments and valued partnerships. And with an estimated $3.4 billion in annual brand sales, we believe we’re just getting started on our mission to maximize the full potential of treatments for patients and physicians around the globe.
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”)
today announced that it has entered into an agreement with the United
States Army Medical Research Institute of Chemical Defense (USAMRICD),
the nation's leading science and technology laboratory in the area of
medical chemical countermeasures research and development, to conduct a
study to evaluate the neuroprotective effects of RYANODEX®
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (NASDAQ: EGRX)
announced today that Scott Tarriff, Chief Executive Officer, and Pete
Meyers, Chief Financial Officer, will present at the Cantor Global
Healthcare Conference as followsSee More
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or “the Company”)
today announced that the Compensation Committee of the Company’s Board
of Directors has approved the appointment of David Pernock to the
position of Chief Operating Officer, effective as of September 1, 2018.
In addition to his new role as Chief Operating Officer, Mr. Pernock will
continue to serve as the Company’s President.
“We areSee More